2022-RA-1380-ESGO Triple negative breast cancer about 24 patients and literature review

Introduction/Background Triple-negative breast cancer (TNBC) is defined by the absence of estrogen and progesterone receptor expression HER2 overexpression or amplification. Epidemiologic clinical features are distinct from other subtypes, including younger age at diagnosis, higher risk relapse despite increased chemosensitivity, incidence lung brain metastases.Indeed, TNBC has pathological features. Due to its aggressive behavior, relatively poor prognosis, lack targeted therapies, associated with high morbidity mortality. Therefore, for several years, neoadjuvant chemotherapy been mainstay treatment. Methodology Our work consists a retrospective study carried out Hassan 2 University Hospital Fez, between January 2016 December 2021, involving 24 cases triple-negative that had undergone surgical Results The results show predominance in patients aged over 35 years still genital activity. Invasive ductal carcinoma most predominant type representing 90% an initial inflammatory aspect 10 patients. Histopronostic grades II III represent each 47.8% cases. In addition, proliferation rate (ki67%) was more than 70% Neoadjuvant prescribed 19 time surgery last treatment less 6 weeks 74% cases.Radical (Patey) performed 18 patients, while only 3 received conservative Despite fact all our adjuvant radiotherapy chemotherapy, 3-year survival 53%. Conclusion Although advances advent remains leading cause death. Current histological classifications do not fully establish prognostic predictive parameters response.